A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
6
Authors
Peter Nägele
Peter Nägele•Ben Palanca•Charles Conway
Published
June 9, 2021
Abstract
Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration.
